Brookfield, EQT close in on Gland Pharma, but rising stock a pain

The Chinese parent has diversified investments that range from healthcare to football clubs, asset management, banks, estate, hospitality, fashion and industrials. The conglomerate has a presence across the pharma value chain from manufacturing to diagnostics and medical devices. Shanghai Fosun Pharmaceutical Co. had acquired an 86% stake in Gland Pharma in 2016 from KKR for a record deal value of $1.26 billion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XMPWGYU
via IFTTT